Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of “Moderate Buy” by Analysts
Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have received an average rating of “Moderate Buy” from the eight research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month […]
More Stories
Enterprise Products Partners Target of Unusually Large Options Trading (NYSE:EPD)
Enterprise Products Partners L.P. (NYSE:EPD – Get Free Report) saw some unusual options trading on Tuesday. Stock traders acquired 34,749...
High Income Securities Fund (NYSE:PCF) Short Interest Update
High Income Securities Fund (NYSE:PCF – Get Free Report) was the recipient of a significant decline in short interest during...
Royalty Pharma Target of Unusually Large Options Trading (NASDAQ:RPRX)
Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) saw some unusual options trading on Tuesday. Stock investors purchased 2,751 call...
Ximen Mining (CVE:XIM) Trading Down 20% – Should You Sell?
Ximen Mining Corp. (CVE:XIM – Get Free Report) fell 20% during mid-day trading on Tuesday . The company traded as...
Short Interest in GraniteShares 2x Long COIN Daily ETF (NASDAQ:CONL) Drops By 41.1%
GraniteShares 2x Long COIN Daily ETF (NASDAQ:CONL – Get Free Report) was the target of a significant decline in short...
Head to Head Contrast: Bicycle Therapeutics (NASDAQ:BCYC) and Sycamore Entertainment Group (OTCMKTS:SEGI)
Sycamore Entertainment Group (OTCMKTS:SEGI – Get Free Report) and Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) are both consumer discretionary...